Compare Amphastar Pharmaceuticals Inc (AMPH) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs General Dynamics Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while General Dynamics Corporation trades at $391.3 (market cap $107.13B). The key difference: General Dynamics Corporation is far larger — about 124× Amphastar Pharmaceuticals Inc's market cap, and General Dynamics Corporation pays a 1.61% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | GD | |
|---|---|---|
Market Cap | $863.95M | $107.13B |
Sector | Health | Industrials |
52-Week High | $30.81 | $395.97 |
52-Week Low | $16.87 | $312.53 |
Enterprise Value | $1.26B | $112.28B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
General Dynamics (GD) trades at $392.05, up 1.33% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $4.24 versus $3.96 expected, with revenue growth across all segments. A $76.6 billion Navy contract awarded in July 2026 bolsters its backlog to $136.5 billion, providing visibility for future growth.
The stock offers upside to the $427.40 consensus price target, driven by defense spending tailwinds and operational execution. Risks include valuation at a 23.91 P/E and potential contract execution delays. Analyst sentiment is positive with 57% buy ratings, but overbought RSI levels near-term may limit gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
